Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance [Yahoo! Finance]
Purple Biotech Ltd. - American Depositary Shares (PPBT)
Company Research
Source: Yahoo! Finance
REHOVOT, Israel, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Examining Division of the European Patent Office has issued an intention to grant a European Patent for Application No. 20168234.1, titled 'Combinations of IRS/STAT3 Dual Modulators and Anti-Cancer Agents for Treating Cancer' This application, if granted, is expected to provide broad protection for NT219 combinations with leading immunotherapies, such as anti-PD-1, PD-L1, CTLA-4, and CD20 antibodies, which are designed to enhance responsiveness in resistant cancers. It further covers combinations of NT219 with MEK inhibitors that may expand treatment sensitivity for resistant tumors. Finally, the application includes claims for combinations of NT219 with selected chemotherapies or targeted agents to address
Show less
Read more
Impact Snapshot
Event Time:
PPBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PPBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PPBT alerts
High impacting Purple Biotech Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
PPBT
News
- Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual CongressGlobeNewswire
- Purple Biotech (NASDAQ:PPBT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PPBT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 PlatformGlobeNewswire
- Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price NotificationGlobeNewswire
- Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor ResistanceGlobeNewswire
PPBT
Sec Filings
- 11/19/25 - Form 6-K
- 11/14/25 - Form 6-K
- 11/7/25 - Form SCHEDULE
- PPBT's page on the SEC website